UNAIDS executive director Winnie Byanyima said that if the US funding is not reinstated or others do not step in to fill the ...
The head of the U.N. AIDS agency says the sudden loss of American money has been "devastating" for efforts to stop HIV and ...
Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...
Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...
Investor's Business Daily on MSN5d
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention FundingGilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback